BioVie Inc., a Nevada-based biopharmaceutical company, has announced that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2), commonly referred to as the Bid Price Rule. This development follows a previous notification from the Nasdaq Listing Qualifications Staff, which had indicated that BioVie's Class A common stock had been trading below the minimum required bid price of $1.00 per share for 30 consecutive business days. The company has now achieved the necessary bid price threshold, maintaining a closing bid price at or above $1.00 per share for at least 10 consecutive business days, from August 6, 2024, to August 19, 2024. BioVie's management has expressed its commitment to continue meeting Nasdaq's listing standards going forward.

BioVie Inc., a Nevada-based biopharmaceutical company, has announced that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2), commonly referred to as the Bid Price Rule. This development follows a previous notification from the Nasdaq Listing Qualifications Staff, which had indicated that BioVie's Class A common stock had been trading below the minimum required bid price of $1.00 per share for 30 consecutive business days. The company has now achieved the necessary bid price threshold, maintaining a closing bid price at or above $1.00 per share for at least 10 consecutive business days, from August 6, 2024, to August 19, 2024. BioVie's management has expressed its commitment to continue meeting Nasdaq's listing standards going forward.